Hansa Biopharma AB announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma AB (publ) announced that it has entered into an agreement for a private placement for proceeds of $70 million on July 18, 2022. The transaction included participation from new investor NovaQuest Capital Management, L.L.C. The transaction is expected to close in 15 days.